Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma
Authors:
Open Access
- 30 March 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Abstract
Lung cancer, specifically the histological subtype lung adenocarcinoma (LUAD), has the highest global occurrence and fatality rate. Extensive research has indicated that RNA alterations encompassing m6A, m5C, and m1A contribute actively to tumorigenesis, drug resistance, and immunotherapy responses in LUAD. Nevertheless, the absence of a dependable predictive model based on m6A/m5C/m1A-associated genes hinders accurately predicting the prognosis of patients diagnosed with LUAD. In this study, we collected patient data from The Cancer Genome Atlas (TCGA) and identified genes related to m6A/m5C/m1A modifications using the GeneCards database. The “ConsensusClusterPlus” R package was used to produce molecular subtypes by utilizing genes relevant to m6A/m5C/m1A identified through differential expression and univariate Cox analyses. An independent prognostic factor was identified by constructing a prognostic signature comprising six genes (SNHG12, PABPC1, IGF2BP1, FOXM1, CBFA2T3, and CASC8). Poor overall survival and elevated expression of human leukocyte antigens and immune checkpoints were correlated with higher risk scores. We examined the associations between the sets of genes regulated by m6A/m5C/m1A and the risk model, as well as the immune cell infiltration, using algorithms such as ESTIMATE, CIBERSORT, TIMER, ssGSEA, and exclusion (TIDE). Moreover, we compared tumor stemness indices (TSIs) by considering the molecular subtypes related to m6A/m5C/m1A and risk signatures. Analyses were performed based on the risk signature, including stratification, somatic mutation analysis, nomogram construction, chemotherapeutic response prediction, and small-molecule drug prediction. In summary, we developed a prognostic signature consisting of six genes that have the potential for prognostication in patients with LUAD and the design of personalized treatments that could provide new versions of personalized management for these patients.Keywords
Funding Information
- Scientific Research Fund Project of Education Department of Yunnan Province (2024Y221, 2024Y221)
- Science and Technology Innovation Team for Precision Pathological Diagnosis of Lung Malignant Tumours at Kunming Medical University (CXTD202210, CXTD202210)
- the Regional Fund Project of the National Natural Science Foundation of China (82360523)
- Xingdian Talent Plan “Famous Doctor Special Project” (RLMY20220018)
This publication has 61 references indexed in Scilit:
- N 1 -methyladenosine modification in cancer biology: Current status and future perspectivesComputational and Structural Biotechnology Journal, 2022
- FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell ProliferationAdvanced Science, 2022
- DNA methylation in lung cancer patients: Opening a "window of life" under precision medicineBiomedicine & Pharmacotherapy, 2021
- Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trialEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Genome-wide identification of transcription factors that are critical to non-small cell lung cancerCancer Letters, 2018
- FOXM1 regulates radiosensitivity of lung cancer cell partly by upregulating KIF20AEuropean Journal of Pharmacology, 2018
- Androgen receptor in triple negative breast cancer: A potential target for the targetless subtypeCancer Treatment Reviews, 2018
- Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationCell, 2018
- Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cellsTumor Biology, 2015
- Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?Cellular and Molecular Life Sciences, 2012